Catalent Pharma Solutions LLC

  • Home
  • Catalent Pharma Solutions LLC

Catalent Pharma Solutions LLC Championing the missions that matter™. Catalent is your trusted partner in transforming lives. Catalyst + Talent. Our name combines these ideas. Catalent develops.

Every medicine, therapy, and product we help develop, manufacture, and deliver reflects our commitment to put patients first. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration o

f development programs and the launch of more than a hundred new products every year. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.

As autologous, allogeneic, iPSC and in vivo approaches continue to advance, sponsors must think ahead about how their CM...
04/09/2026

As autologous, allogeneic, iPSC and in vivo approaches continue to advance, sponsors must think ahead about how their CMC strategies can support scale, manage cost and maintain safety and efficacy on the path to commercialization.

Join Catalent’s John Tomtishen, Bruno Marques of Morphocell Technologies, Karen Walker, former CTO of Kyverna Therapeutics, and Marty Giedlin of RegCell for our upcoming webinar, "Preparing for the next decade in cell therapy: How sponsors can evolve their CMC strategies for commercial success across modalities."

Together, the panel will share perspectives on the evolving CMC requirements across cell therapy modalities and discuss how sponsors can navigate key manufacturing and commercialization considerations as the field matures.

Secure your spot to learn how a forward-looking CMC strategy can help position cell therapy programs for long-term commercial success.

Register here: https://ow.ly/RteW50ZIWXg

Choosing the right manufacturing platform can shape the future scalability and economics of a cell therapy program.As th...
03/09/2026

Choosing the right manufacturing platform can shape the future scalability and economics of a cell therapy program.

As the industry gathers at Advanced Therapies Europe, Catalent is looking forward to discussing how early manufacturing decisions can help developers improve efficiency, manage costs, and prepare programs for long-term commercial success.

Our latest expert content explores the considerations behind choosing between modular and fully integrated cell therapy manufacturing platforms, including scalability, flexibility, automation, cost, and the distinct requirements of autologous and allogeneic therapies.

Continue the conversation at Advanced Therapies Europe with John Tomtishen, Global Head of Field Application Scientists & Strategic Alliances at Catalent, during the panel discussion:

CMC Cost of Goods: The Red Flag We Can’t Ignore – How Advanced Therapies Fix the Economics Before Scale Makes It Worse
September 9 | 13:00–13:30

Explore the expert content to learn how thoughtful platform selection and early planning can help streamline manufacturing transitions and build scalability into your program: https://ow.ly/j3KW50ZIWNU

What will it take to scale AAV manufacturing without compromising quality, safety, or clinical momentum?As the advanced ...
03/09/2026

What will it take to scale AAV manufacturing without compromising quality, safety, or clinical momentum?

As the advanced therapies community comes together at Advanced Therapies Europe, Catalent is looking forward to discussing the technologies and strategies helping address some of the most persistent challenges facing gene therapy developers.

One example is RepCapExcel™, a Catalent innovation designed to address the yield limitations of transient transfection-based AAV manufacturing. Delivering up to 3–6X higher titers, RepCapExcel™ has the potential to increase manufacturing productivity and support the scalability and commercial viability of AAV programs.

Continue the conversation at Advanced Therapies Europe with Philip Wills, Chief Commercial Officer at Catalent, during his fireside chat:

AAV at Scale Without Compromise: How the Field Is Fixing Manufacturing Bottlenecks and Toxicity Risk Without Slowing Clinical Momentum
September 8 | 14:30–15:00

Explore the expert content and learn more about approaches to overcoming AAV manufacturing challenges: https://ow.ly/YeGL50ZIP7C

Catalent is proud to host the 2026 BioNJ Manufacturing Summit at its Cell Therapy Center of Excellence in Princeton, New...
02/09/2026

Catalent is proud to host the 2026 BioNJ Manufacturing Summit at its Cell Therapy Center of Excellence in Princeton, New Jersey.

BioNJ's Manufacturing Summit brings together industry leaders to discuss the trends, challenges, and opportunities driving the next generation of biopharmaceutical manufacturing.

The program features a carefully curated agenda focused on some of the industry's most important topics, including:
• State of Biopharma Manufacturing in New Jersey
• Small & Large Molecule Manufacturing: Past, Present & Future
• Supply Chain Resilience, Onshoring & Risk Management
• Scaling Cell & Gene Therapy Manufacturing: Innovation, Cost & Access
• Investment & Growth in New Jersey Manufacturing, Including Biosimilars & Advanced Therapies
• Patient Perspectives: Access, Outcomes & Impact

As a special highlight, attendees will have the opportunity to tour Catalent's state-of-the-art Princeton manufacturing facility, providing a firsthand look at the technologies, expertise, and innovation advancing the future of biomanufacturing.

Reserve your spot today: https://ow.ly/n4oF50ZImeF

02/09/2026

Every therapy begins as a molecule, and Catalent is there to support its development at every stage, from preclinical and Phase 1 through approval and commercial manufacturing. This end-to-end perspective shapes the way we partner with innovators, supporting more than 1,000 active development programs and producing more than 60 billion doses a year.

In part two of this series, President and CEO Alessandro Maselli explores Catalent’s “Follow the Molecule” strategy. Find out what it means to Catalent to partner across the development lifecycle, supporting customers to navigate complexity, accelerate progress and ultimately improve patient lives.

Watch the video below and read the full The CEO Magazine - North America cover story here: https://ow.ly/tPSM50ZIgck

As cell therapy expands across modalities and into new disease areas, a robust CMC strategy is becoming increasingly cri...
01/09/2026

As cell therapy expands across modalities and into new disease areas, a robust CMC strategy is becoming increasingly critical to long-term commercial success.

Join Catalent’s John Tomtishen alongside Bruno Marques of Morphocell Technologies, Karen Walker, former CTO of Kyverna Therapeutics, and Marty Giedlin of RegCell for our upcoming webinar titled "Preparing for the next decade in cell therapy: How sponsors can evolve their CMC strategies for commercial success across modalities".

Our panel will explore how CMC strategies are evolving across autologous, allogeneic, iPSC and in vivo cell therapies, including the challenges of balancing cost, scalability, safety, efficacy and commercial viability.

Secure your place today to hear perspectives from industry experts and discover how sponsors can prepare their CMC strategies for the next generation of cell therapies.

Register here: https://ow.ly/JFxJ50ZHNL7

31/08/2026

September is shaping up to be a busy month for the Catalent Cell & Gene Therapy team.

Our experts, Philip Wills, John Tomtishen, and Frédéric Cédrone, will be speaking at leading industry events across Europe and the U.S., sharing insights on the opportunities, challenges, and innovations shaping the future of advanced therapies.

From AAV gene therapies and iPSC-based platforms to autologous and allogeneic cell therapy approaches, our team will be discussing key trends, manufacturing considerations, and strategies to help advance the next generation of therapies.

See where you can connect with the team this September. 👇

Attending one of these events? Schedule time with our experts to continue the conversation:
http://catalent.com/contact?utm_campaign=FY26-TOP-LEVEL-Content-PARENT-Mar26-Dec26&utm_medium=social&utm_source=linkedin&utm_term=701Up00000b6tFrIAI&utm_content=CGT-Event-

Stick packs are creating new possibilities for patient-centric oral drug delivery and can enable advanced formulation st...
28/08/2026

Stick packs are creating new possibilities for patient-centric oral drug delivery and can enable advanced formulation strategies including taste masking, bioavailability enhancement and the delivery of high drug-load products.

Join our upcoming webinar to explore how smart formulation strategies and an integrated development, manufacturing and packaging approach can help reduce risk and accelerate the path to patients.

Register now to unlock the potential of stick packs: https://ow.ly/V7n250ZGCrh 👈

27/08/2026

Navigating clinical supply across global markets requires the right strategy, infrastructure, and local expertise.

Discover how Catalent’s clinical supply capabilities in China can help sponsors leverage Free Trade Zones to simplify global supply strategies, navigate import and export complexities, and support more efficient clinical trial ex*****on.

Learn how the right clinical supply approach can help you reach patients across China and beyond with greater confidence.

Watch the video: https://ow.ly/zHYp50ZG0w7

A big thank you to everyone who attended our Cell Therapy Industry Day in Princeton, NJ last week.The event brought toge...
27/08/2026

A big thank you to everyone who attended our Cell Therapy Industry Day in Princeton, NJ last week.

The event brought together members of the cell therapy community for insightful discussions on the evolving regulatory and commercial landscape, emerging opportunities in advanced therapies, and the future of cell therapy development and manufacturing.

We enjoyed hosting attendees at our Cell Therapy Center of Excellence, sharing our capabilities, and facilitating valuable networking and collaboration.

Thank you for helping make the event a success. We look forward to staying connected and continuing the conversation.

Address

NJ

Telephone

+17325376200

Website

Alerts

Be the first to know and let us send you an email when Catalent Pharma Solutions LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Catalent Pharma Solutions LLC:

Shortcuts

  • Want your business to be the top-listed Business?

Share